Literature DB >> 2580176

Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension.

A C Simon, J A Levenson, J Bouthier, B Maarek, M E Safar.   

Abstract

The effects of angiotensin-converting enzyme inhibition on large arteries have been examined in uncomplicated essential hypertensive patients (grade 1-2 WHO). These effects were determined from (a) changes in arterial compliance as measured from the slope of the decline in arterial pressure during diastole and (b) alterations in diameter of the brachial artery and blood flow velocity within its lumen, as assessed by pulsed Doppler velocimetry. Both acute and chronic ACE inhibition were accompanied by a significant increase in arterial compliance and a dilation of the brachial artery. This response might be related to changes in plasma and/or intraarterial angiotensin and/or to changes in plasma potassium. Whatever their mechanism, the arterial dilatation and increase in compliance would improve the buffering and the conducting functions of the large arteries, and these in turn may, if persistent, prove beneficial in possibly preventing arterial complications of hypertension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580176     DOI: 10.1097/00005344-198507001-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?

Authors:  Henry Fok; J Kennedy Cruickshank
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 2.  Heterogeneity of response of peripheral arteries to antihypertensive drugs in essential hypertension. Basic effects and functional consequences.

Authors:  J Levenson; A Simon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta.

Authors:  K Breithaupt-Grögler; M Leschinger; G G Belz; R Butzer; K Erb; C de May; W Sinn
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 4.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 5.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

7.  The effect of oral cilazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human dorsal hand veins.

Authors:  G G Belz; C Beermann; J Schloos; C H Kleinbloesem
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

8.  Differential systemic and regional hemodynamic profiles of four angiotensin-I converting-enzyme inhibitors in the rat.

Authors:  C Richer; M P Doussau; J F Giudicelli
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

9.  Chronic antihypertensive treatment with captopril plus hydrochlorothiazide improves aortic distensibility in the spontaneously hypertensive rat.

Authors:  J M Chillon; C Capdeville-Atkinson; I Lartaud; J Guillou; P M Mertès; J Atkinson
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.